Pesquisas alternativas:
doses develop » loss develop (Expandir a Pesquisa), models develop (Expandir a Pesquisa), locus develop (Expandir a Pesquisa)
develop type » developing type (Expandir a Pesquisa)
dna develop » a develop (Expandir a Pesquisa), 133a develop (Expandir a Pesquisa), cd38 develop (Expandir a Pesquisa)
drug doses » drug dose (Expandir a Pesquisa), drug disease (Expandir a Pesquisa)
doses develop » loss develop (Expandir a Pesquisa), models develop (Expandir a Pesquisa), locus develop (Expandir a Pesquisa)
develop type » developing type (Expandir a Pesquisa)
dna develop » a develop (Expandir a Pesquisa), 133a develop (Expandir a Pesquisa), cd38 develop (Expandir a Pesquisa)
drug doses » drug dose (Expandir a Pesquisa), drug disease (Expandir a Pesquisa)
21
Por Mellinas-Gomez, Maria, Spanswick, Victoria J., Paredes-Moscosso, Solange R., Robson, Matthew, Pedley, R. Barbara, Thurston, David E., Baines, Stephen J., Stell, Anneliese, Hartley, John A.
Publicado no BMC Vet Res (2015)
“.... There is clearly a need to develop more effective anti-cancer drugs in dogs. SG2000 (SJG-136) is a sequence...”Publicado no BMC Vet Res (2015)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
22
Por Babazadeh, Beheshteh, Sadeghnia, Hamid Reza, Safarpour Kapurchal, Elham, Parsaee, Heydar, Nasri, Sima, Tayarani-Najaran, Zahra
Publicado em 2012
“... of the molecular mechanisms of neuronal damage during ischemia and for the development of neuroprotective drugs...”Publicado em 2012
Obter o texto integral
Obter o texto integral
Artigo
23
Por Chen, Chung-Yi, Yen, Ching-Yu, Wang, Hui-Ru, Yang, Hui-Ping, Tang, Jen-Yang, Huang, Hurng-Wern, Hsu, Shih-Hsien, Chang, Hsueh-Wei
Publicado no Toxins (Basel) (2016)
“...The development of drugs that selectively kill oral cancer cells but are less harmful to normal...”Publicado no Toxins (Basel) (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
24
Por Donejko M, Przylipiak A, Rysiak E, Miltyk W, Galicka E, Przylipiak J, Zaręba I, Surazynski A
Publicado em 2015-11-01
“...Drug Design, Development and Therapy...”Publicado em 2015-11-01
Obter o texto integral
Artigo
25
26
Por Senbabaoglu, Filiz, Cingoz, Ahmet, Kaya, Ezgi, Kazancioglu, Selena, Lack, Nathan A., Acilan, Ceyda, Bagci-Onder, Tugba
Publicado no Cancer Biol Ther (2016)
“... response without any effect on their own. One such drug, Mitoxantrone, a DNA-damaging agent, did not cause...”Publicado no Cancer Biol Ther (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
27
Por De Clercq, E
Publicado em 1997
“...-bromovinyl)-2'-deoxyuridine (BVDU [brivudin]) for the therapy of herpes simplex virus type 1 and varicella...”Publicado em 1997
Obter o texto integral
Obter o texto integral
Artigo
28
Por Gonçalves, António Pedro, Máximo, Valdemar, Lima, Jorge, Singh, Keshav K., Soares, Paula, Videira, Arnaldo
Publicado em 2011
“... with the drug for a longer period become senescent. Treatment of mtDNA-depleted cells with rotenone induces cell...”Publicado em 2011
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
29
“... to these drugs ultimately resulting in treatment failure and cancer progression. Causes for chemotherapy failure...”
Obter o texto integral
Obter o texto integral
Artigo
30
Por Staib, Peter, Moran, Gary P., Sullivan, Derek J., Coleman, David C., Morschhäuser, Joachim
Publicado em 2001
“... of the drug benomyl strongly activated the reporter gene fusion in a dose-dependent fashion, demonstrating...”Publicado em 2001
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
31
Por Srivastava, Apurva K., Navas, Tony, Herrick, William G., Hollingshead, Melinda G., Bottaro, Donald P., Doroshow, James H., Parchment, Ralph E.
Publicado no Ann Transl Med (2017)
“... over 20 years of drug development to target MET in cancers, a pure anti-MET therapeutic has not yet...”Publicado no Ann Transl Med (2017)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
32
Por Singh, Sheo B., Kaelin, David E., Wu, Jin, Miesel, Lynn, Tan, Christopher M., Meinke, Peter T., Olsen, David, Lagrutta, Armando, Bradley, Prudence, Lu, Jun, Patel, Sangita, Rickert, Keith W., Smith, Robert F., Soisson, Stephen, Wei, Changqing, Fukuda, Hideyuki, Kishii, Ryuta, Takei, Masaya, Fukuda, Yasumichi
Publicado em 2014
“... necessitating the discovery of new agents. Bacterial type II topoisomerase is a clinically validated, highly...”Publicado em 2014
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
33
“..., and phenotypic resistance to drug-induced toxicity through upregulated xenobiotic metabolism or DNA repair...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
34
Por Jingmin Zhang, Yafeng Wang, Youmei Peng, Chongzhen Qin, Yixian Liu, Jingjing Li, Jinhua Jiang, Yubing Zhou, Junbiao Chang, Qingduan Wang
Publicado em 2018-11-01
“... showed that NCC inhibited DNA replication and HBeAg production in wild-type or lamivudine-resistant HBV...”Publicado em 2018-11-01
Obter o texto integral
Artigo
35
“... drugs suppressed HSV replication in a dose-related manner. In the continued presence of the drugs, HSV...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
36
“.... Effects depend on dose, type, and reactivity of the drug, and the age of the individual. Evidence suggests...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
37
Por Gang Qian, Dandan Liu, Junfa Hu, Fang Gan, Lili Hou, Nianhui Zhai, Xingxiang Chen, Kehe Huang
Publicado em 2018-02-01
“... infections and autophagy may be a potential marker to develop novel anti-PCV2 drugs....”Publicado em 2018-02-01
Obter o texto integral
Artigo
38
Por Hussein, D, Holt, S V, Brookes, K E, Klymenko, T, Adamski, J K, Hogg, A, Estlin, E J, Ward, T, Dive, C, Makin, G W J
Publicado em 2009
“... problematic for several paediatric tumour types. The urgent need to access novel agents to treat drug...”Publicado em 2009
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
39
Por Kim, Yeo-Jung, Lee, Hae-June, Kim, Tae-Min, Eisinger-Mathason, TS Karin, Zhang, Alexia Y, Schmidt, Benjamin, Karl, Daniel L, Nakazawa, Michael S, Park, Peter J, Simon, M Celeste, Yoon, Sam S
Publicado em 2013
“... chemotherapeutic drug for sarcomas, doxorubicin (Dox), was recently found to block HIF-1α binding to DNA at low...”Publicado em 2013
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
40
Por Bodo, Sahra, Svrcek, Magali, Sourrouille, Isabelle, Cuillières-Dartigues, Peggy, Ledent, Tatiana, Dumont, Sylvie, Dinard, Laetitia, Lafitte, Philippe, Capel, Camille, Collura, Ada, Buhard, Olivier, Wanherdrick, Kristell, Chalastanis, Alexandra, Penard-Lacronique, Virginie, Fabiani, Bettina, Fléjou, Jean-François, Brousse, Nicole, Beaugerie, Laurent, Duval, Alex, Muleris, Martine
Publicado no Oncotarget (2015)
“... they escape apoptosis resulting from MMR-dependent signaling of drug-induced DNA damage. Prolonged treatment...”Publicado no Oncotarget (2015)
Obter o texto integral
Obter o texto integral
Artigo